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Abstract 
COVID-19 (Coronavirus disease 2019) is a public health emergency of international con-
cern. There is a pressing urgency to find treatments based upon currently available scien-
tific knowledge and epidemiological data. In this article, we provide a novel hypothesis 
describing how the severity of the pathology is mainly resulting from the Antibody re-
sponses to SARS-CoV-2 (virus causing COVID-19) and not due to the direct action of the 
virus. SARS-CoV-2 appears to alter the endothelial cell. The pathophysiological mecha-
nism is not yet elucidated. The damage caused resembles a systemic, multi-organ vascu-
litis predominantly in the lungs. An increase in thromboembolic complications has been 
observed in COVID-19 patients. These are manifested by pulmonary embolisms or sys-
temic microembolism manifested by microangiopathy affecting the lungs, brain, liver, 
kidneys and intestines. Therefore, we hypothesize that an auto-immune acquired Protein 
S (PS) deficiency may be involved in the pathogenesis of thrombotic events in Covid-19. 
Auto-antibodies to Protein S may form immune complexes, inducing increased clearance 
of PS or interfering with the protein C-protein S system. COVID-19 early thromboprophy-
laxis in infected patients, or even effective anticoagulation, could prevent the progression 
to severe forms, thus reducing mortality in patients with COVID-19. Activated Protein C 
(APC), a physiological coagulation inhibitor with cytoprotective properties, could be an 
interesting avenue for the treatment of severe forms of the disease in intensive care; its 
administration in hypoxic patients could improve tissue oxygenation. Randomized resus-
citation studies in patients with COVID19 are also needed to confirm our hypothesis. 
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INTRODUCTION 
SARS COV  is a single-stranded RNA virus, be-
longing to the coronavirus family, of positive polar-
ity, of approximately 30 kilobases, which repli-
cates in the cytoplasm of host cells; the 5' end of 
the genome has a cap-like structure and the 3' 
end of the genome has a 3' end, has a polyA tail. 
This virus is enveloped and has on its surface 
peplomeric structures called spicules. 
An epidemic of atypical pneumonia, known as 
Severe Acute Respiratory Syndrome (SARS), 
spread to various countries (Vietnam, Hong Kong, 
Singapore, Thailand and Canada) during the first 
quarter of 2003, following an initial outbreak in 
China in the last quarter of 2002. The severity of 
the disease is such that the mortality rate is ap-
proximately 3 to 6%.  
The determination of the causative agent of this 
disease has been undertaken by many laborato-
ries around the world. In March 2003, a new coro-
navirus (SARS-CoV, SARS virus or SARS virus, 
in French) was isolated, in association with cases 
of the severe acute respiratory syndrome. 
(Ksiazek et al., 2003;  Drosten et al., 2003; Peiris 
et al., 2003; Sean Wei Xiang Lee et al., 2020). No 
treatment or vaccine has been developed against 
this virus so far. 
A second strain emerged in December 2019 in 
WUHUN (SARS-COV 2) and spread in pandemic 
mode. COVID 19 is currently a global health prob-
lem with health, safety, security, economic and 
social implications. 
SARS-COV 2 as a serious and deadly virus: 
The virus has a very high contagion potential, and 
it can spread rapidly in an exponential pattern 
contaminating thousands of people in the absence 
of barrier measures and strict means of contain-
ment. The disease is highly contagious. No coun-
try is spared. 
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The virus causes cellular lesions in the lungs 
causing acute respiratory distress with a rapid 
evolution requiring recourse to mechanical ventila-
tion and a mortality rate that varies between 1 and 
10 percent. 
A vascular tropism: COVID 19 is a vasculitis: 
The virus appears to alter the endothelial cell: The 
pathophysiological mechanism is not yet elucidat-
ed, however, the SARS-COV 2  S protein (a major 
antigenic determinant of the virus) has a high af-
finity for cellular angiotensin-2 receptors using the 
angiotensin-2 converting enzyme (ACE2) to enter 
host cells (Hofmann et al., 2020). These ACE2 
receptors are highly expressed at the endothelial 
level in the lungs, brain, gastrointestinal tract, liver 
and kidney. This suggests that the damage 
caused resembles a systemic, multi-organ vascu-
litis predominantly in the lungs.    
Role of S protein in frequent and serious 
thromboembolic complications: The Spike pro-
tein is the major antigenic protein of coronavirus-
es: the S1 domain contains most of the epitopes 
recognized by neutralizing antibodies during infec-
tion (Godet et al., 1994; Hofmann et al., 2004; 
Sayaka et al., 1991; Walls et al., 2020), although 
sites have been described in other regions of the 
S protein  (YangYang et al., 2014). 
S Protein  plays a major role in viral entry 
(Belouzard et al.,2012). It is a strongly N-
glycosylated type I transmembrane protein of 180 
to 200 kDa that assembles into homotrimers on 
the surface of the viral particle  (Delmas et Laude, 
1990). It has a long N-terminal domain and a short 
C-terminal domain. It plays a double function in 
the viral entry by allowing on the one hand the 
binding of the cell receptor and on the other hand 
the fusion of the viral envelope with the mem-
branes of the target cells. It has a decisive role in 
cellular tropism and pathogenicity  (Hulswit et al., 
2016).  
It appears that patients who have been infected 
with CoV-SARS retain antibodies to the receptor-
binding domain (RBD) of S protein for at least 3 
years after infection of Spike protein  (Cao et al., 
2010). 
The attachment of the virion to the host cell is initi-
ated by interactions between the RBD of  S pro-
tein and its receptor, which determines the host 
spectrum, but also the tissue tropism of the coro-
navirus. CoV-SARS uses the enzyme conversion 
of angiotensin 2 (ACE2) to enter host cells  
(Hofmann et al., 2005). 
The neutralization of infection by antibodies is a 
mechanism of protection against viruses. Infection 
can be inhibited by blocking binding to cell recep-
tors or by interfering with viral fusion. In addition, 
in the case of enveloped viruses, antibodies can 
recruit effector cells or complement, allowing the 
destruction of infected cells or lysis of viral parti-
cles  (Corti et Lanzavecchia, 2013). 
The seroconversion time of Antibodies, IgM and 
IgG antibodies appeared consequently with a me-
dian seroconversion day of 11, 12 and 14 respec-
tively. There is a strong positive correlation be-
tween clinical severity and antibodies titer since 2- 
weeks after illness onset, for the first time in 
COVID-19 patients. The high Antibodies titer may 
be considered as a risk factor of critical illness, 
independently from older age, male gender and 
comorbidities (Zhao et al., 2020). 
An increase in thromboembolic complications has 
been observed in COVID 19. These are manifest-
ed by pulmonary embolisms or systemic microem-
bolisms manifested by microangiopathy affecting 
the lungs, brain, liver, kidneys and intestines. The 
retina may be affected.The virus has the ability to 
make the endothelium pro clotting by activating it 
and causing lesions. These thromboembolic com-
plications are usually observed during the second 
week of the disease period corresponding to the 
antibody seroconversion time.  
Plasma protein S, discovered in Seattle, is a 69 
KDa-dependent vitamin K glycoprotein synthe-
sized by hepatocytes, endothelial cells, megakar-
yocytes and osteoblasts. Its synthesis requires the 
presence of vit K. Its half-life is 42 h and its plasma 
concentration is 25 mg /l. It plays a major role in the 
inhibition of coagulation factors. A constitutional or 
acquired deficiency causes thromboembolic diseas-
es. Protein S also plays an important role in the im-
mune response by promoting apoptosis. 
A secondary deficiency of free protein S caused 
by COVID-19 is strongly implicated in the genesis 
of these thromboembolic complications. The in-
flammatory syndrome, by increasing the concen-
tration of Human Complement C4b-binding protein 
(C4BP), leads to a decrease in the free fraction of 
protein S (Van de poel et al, 1999). Anti-S protein 
antibodies, synthesized during the immune re-
sponse, can lead to a secondary deficiency as in 
the case of the varicella and Lupus (Rashid Khan 
et al, 2019). 
The dosage of protein S in patients with COVID-
19 is an interesting lead that could objectify a sec-
ondary deficit and confirm our hypothesis. 
The severity of the pathology resulting from the 
host's immune response and not due to the direct 
action of the virus. The severity of symptoms is 
proportionally related to the increase in antibody 
levels. Indeed, these antibodies directed to neu-
tralize the virus induce a secondary deficit or dys-
function in plasma protein S responsible for throm-
boembolic events. Activated protein C, a physio-
logical inhibitor of coagulation, is an interesting 
therapeutic agent in severe forms of the disease. 
Conclusion 
In conclusion, we propose, a new concept linking 
the severity of the pathology to the Antibody re-
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sponses to SARS-CoV-2. Specifically, COVID-19 
infection stimulates the production of anti-Spike 
protein antibodies developed against this viral 
protein. Due to similarities between this protein 
and protein S, the antibodies attack protein S re-
sulting in its reduction or dysfunction. This, in turn 
promote thrombosis. The hypothesis might be 
further challenged by additional clinical studies 
and by experimental observations measuring pro-
tein S and anti-protein S antibodies in patients 
with COVID-19 in the intensive care unit.  
As a consequence, an immunosuppressive treat-
ment such as hydroxychloroquine or an immuno-
modulatory drugs such as tocilizumab may be 
suggested in controlling the disease in early forms 
by reducing the host's immune response. Early 
thromboprophylaxis in infected patients, or even 
effective anticoagulation, could prevent the pro-
gression to severe forms and thromboembolic 
complications, thus reducing severe forms and 
mortality in patients with COVID19. Activated pro-
tein C, a physiological coagulation inhibitor with 
cytoprotective properties, could be an interesting 
avenue for the treatment of severe forms of the 
disease in intensive care; its administration in hy-
poxic patients could improve tissue oxygenation. It 
is hoped that this hypothesis will serve as a stimu-
lus for further investigation into this issue, through 
randomized resuscitation studies in patients with 
COVID19. 
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